Fortrea (NASDAQ:FTRE) Price Target Lowered to $12.00 at Barclays

Fortrea (NASDAQ:FTRE) had its target price dropped by Barclays from $15.00 to $12.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Barclays‘s target price suggests a potential upside of 15.37% from the stock’s current price.

FTRE has been the subject of several other reports. Wedbush set a $21.00 price objective on Fortrea in a research report on Thursday, December 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fortrea in a research note on Thursday, January 22nd. Robert W. Baird dropped their price target on Fortrea from $19.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday. TD Cowen increased their price target on Fortrea from $7.00 to $15.00 and gave the stock a “hold” rating in a report on Thursday, January 22nd. Finally, Mizuho set a $15.00 price objective on shares of Fortrea in a research note on Friday, January 9th. Four investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $16.15.

Fortrea Trading Down 3.7%

Shares of NASDAQ FTRE traded down $0.40 during midday trading on Friday, reaching $10.40. The stock had a trading volume of 277,260 shares, compared to its average volume of 1,677,578. The company’s 50 day moving average price is $15.28 and its 200 day moving average price is $12.28. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.00 and a current ratio of 1.00. Fortrea has a twelve month low of $3.97 and a twelve month high of $18.67. The firm has a market cap of $961.05 million, a price-to-earnings ratio of -0.93, a price-to-earnings-growth ratio of 0.30 and a beta of 1.59.

Fortrea (NASDAQ:FTRE) last announced its earnings results on Thursday, February 26th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.07). The firm had revenue of $660.50 million for the quarter, compared to the consensus estimate of $665.22 million. Fortrea had a positive return on equity of 5.64% and a negative net margin of 36.77%. As a group, sell-side analysts expect that Fortrea will post 0.51 EPS for the current year.

Hedge Funds Weigh In On Fortrea

A number of institutional investors have recently modified their holdings of FTRE. Larson Financial Group LLC grew its position in Fortrea by 136.7% in the 4th quarter. Larson Financial Group LLC now owns 1,856 shares of the company’s stock valued at $32,000 after purchasing an additional 1,072 shares during the period. Toronto Dominion Bank acquired a new position in Fortrea during the fourth quarter worth $51,000. Nisa Investment Advisors LLC lifted its stake in shares of Fortrea by 214.3% in the third quarter. Nisa Investment Advisors LLC now owns 3,341 shares of the company’s stock valued at $28,000 after buying an additional 2,278 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Fortrea by 27.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,490 shares of the company’s stock valued at $77,000 after buying an additional 980 shares in the last quarter. Finally, Allworth Financial LP grew its holdings in shares of Fortrea by 6,802.4% during the second quarter. Allworth Financial LP now owns 5,660 shares of the company’s stock valued at $28,000 after buying an additional 5,578 shares during the last quarter.

Key Headlines Impacting Fortrea

Here are the key news stories impacting Fortrea this week:

• Positive Sentiment: Management said revenue and adjusted EBITDA were delivered in line with previously communicated full‑year targets and that full‑year cost savings exceeded prior targets — a sign that operating improvements are progressing. GlobeNewswire Release
• Neutral Sentiment: Company issued FY‑2026 revenue guidance of roughly $2.6B–$2.7B (near consensus but at the lower end), which frames expectations for 2026 growth but does not represent a large beat. Guidance Release
• Neutral Sentiment: Analyst coverage remains constructive in tone — Robert W. Baird kept an “outperform” rating but trimmed its price target from $19 to $16, signaling confidence in the story while lowering near‑term upside expectations. Benzinga Note
• Negative Sentiment: Reported quarterly EPS missed Street expectations. Most outlets cite $0.09 EPS vs. a $0.16 consensus; some transcripts show larger GAAP/adjusted differences, increasing investor concern about one‑time items and earnings quality. Zacks Coverage Earnings Call Transcript (InsiderMonkey)
• Negative Sentiment: Revenue slightly missed analyst estimates (reported ~$660.5M vs. ~$665.2M consensus), which, combined with the EPS miss, is driving the negative price reaction despite cost‑savings progress. Yahoo Finance

About Fortrea

Fortrea, Inc is a global contract development and manufacturing organization (CDMO) that provides integrated solutions for pharmaceutical and biotechnology companies. Established as a spin-off from Thermo Fisher Scientific’s Pharma Services business in October 2023, Fortrea leverages a legacy of scientific expertise and manufacturing scale to support drug development from early-stage research through commercial production. The company’s comprehensive offerings address the complex needs of both small-molecule and biologics programs, making it a single source for clients seeking to accelerate timelines and manage costs.

Fortrea’s core services encompass analytical and formulation development, process optimization, clinical and commercial manufacturing, and packaging services.